Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial (Q51478110)

From Wikidata

Jump to navigation Jump to search

scientific article published in March 2007

Language	Label	Description	Also known as
English	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial	scientific article published in March 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

M A Nauck

1

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

G Meininger

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

D Sheng

3

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

L Terranella

4

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

P P Stein

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

Sitagliptin Study 024 Group

6

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

9

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

194-205

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Metformin: new understandings, new uses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Fat in the liver and insulin resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00704.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2006.00704.X

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17300595

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51478110&oldid=2275720146"